HomeCompareBMY vs PXD

BMY vs PXD: Dividend Comparison 2026

BMY yields 4.17% · PXD yields 4.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PXD wins by $1950.70M in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
PXD
PXD
● Live price
4.06%
Share price
$269.62
Annual div
$10.94
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1950.82M
Annual income
$1,862,635,547.63
Full PXD calculator →

Portfolio growth — BMY vs PXD

📍 PXD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYPXD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + PXD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
PXD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
PXD
Annual income on $10K today (after 15% tax)
$344.89/yr
After 10yr DRIP, annual income (after tax)
$1,583,240,215.49/yr
At 15% tax rate, PXD beats the other by $1,583,206,365.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + PXD for your $10,000?

BMY: 50%PXD: 50%
100% PXD50/50100% BMY
Portfolio after 10yr
$975.47M
Annual income
$931,337,685.65/yr
Blended yield
95.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PXD right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
PXD
Analyst Ratings
43
Buy
24
Hold
3
Sell
Consensus: Buy
Price Target
$254.09
-5.8% upside vs current
Range: $196.00 — $347.00
Altman Z
4.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
PXD buys
0
No recent congressional trades found for BMY or PXD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYPXD
Forward yield4.17%4.06%
Annual dividend / share$2.49$10.94
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%100%
Portfolio after 10y$120.5K$1950.82M
Annual income after 10y$39,823.66$1,862,635,547.63
Total dividends collected$91.0K$1944.52M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$254.09

Year-by-year: BMY vs PXD ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrPXD PortfolioPXD Income/yrGap
1← crossover$11,271$571.12$11,512$811.51$241.00PXD
2$12,884$824.20$14,063$1,746.12$1.2KPXD
3$14,993$1,206.32$19,035$3,987.30$4.0KPXD
4$17,839$1,797.27$30,455$10,087.67$12.6KPXD
5$21,826$2,738.11$62,755$30,167.77$40.9KPXD
6$27,643$4,289.31$183,339$116,191.48$155.7KPXD
7$36,534$6,955.64$830,668$634,494.75$794.1KPXD
8$50,861$11,770.13$6,262,177$5,373,362.05$6.21MPXD
9$75,402$20,980.23$82,416,983$75,716,453.96$82.34MPXD
10$120,504$39,823.66$1,950,821,719$1,862,635,547.63$1950.70MPXD

BMY vs PXD: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

PXDStock

Pioneer Natural Resources Company operates as an independent oil and gas exploration and production company in the United States. The company explores for, develops, and produces oil, natural gas liquids (NGLs), and gas. It has operations in the Midland Basin in West Texas. As of December 31, 2021, the company had proved undeveloped reserves and proved developed non-producing reserves of 130 million barrels of oil, 92 million barrels of NGLs, and 462 billion cubic feet of gas; and owned interests in 11 gas processing plants. Pioneer Natural Resources Company was founded in 1997 and is headquartered in Irving, Texas.

Full PXD Calculator →
📬

Get this BMY vs PXD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.